Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu AF28996 in Parkinson's Disease
NCT04291859Phase 1Completed
- Sponsor
- Lundbeck
- Start
- Feb 2020
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label, single-arm trial of Lu AF28996 in Parkinson's disease (PD), sponsored by Lundbeck. Primary endpoints: Number of Participants with Treatment-emergent Adverse Events at 5.5 months, Maximum Plasma Concentration and 1 more. Started Feb 2020; status: completed.
02
Drugs
Lu AF28996
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04291859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04291859.